Induced Pluripotent Stem Cell (iPSC) Media and Reagents …
By daniellenierenberg
Advancing your induced pluripotent stem cells or human embryonic stem cell therapy research to clinical applications requires careful material selection because the quality of starting materials significantly impact the properties of your final stem cell therapy product. Gibco CTS products have been developed to ease the transition from stem cell therapy research to clinical applications by providing high quality GMP manufactured, commercial scale ancillary materials with a high degree of qualification, traceability and regulatory documentation. In an effort to help you maximize the potential of your stem cell research and therapy, and simplify the transition to clinic-ready processes, we offer an extensive selection of research use stem cell research products with complementary CTS formulations. Our CTS products are used in commercially approved cell therapies as well as over 100 clinical trials and are backed by our professional regulatory support and over 30 years of GMP manufacturing experience.
Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) , sometimes collectively referred to as pluripotent stem cells (PSCs), are cells that have the ability to renew themselves indefinitely and differentiate into almost any cell type when exposed to the right microenvironment. These unique properties enable the application of induced pluripotent stem cells and embryonic stem cells in disease modeling, drug discovery, drug toxicity testing, and cell therapy. Strikingly, most embryonic stem cell and induced pluripotent stem cell applications have the potential to improve human health, none more directly so than ESC or iPSC therapy. The most intuitive approach for ES or iPS cell therapy is to transplant PSC-derived cells for the direct replacement of damaged or degenerated cells or tissue. However, there are many other approaches to ES or iPS stem cell therapy such as transplanting PSC-derived cells that then release signals triggering endogenous repair mechanisms.
At Thermo Fisher Scientific, we support the development of your human embryonic stem cell therapy or induced pluripotent stem cell therapy from the earliest stages of research and all the way to the clinic. We offer high-quality products across the iPS cell therapy workflow from reprogramming to differentiation. Most Gibco media and supplements for culture and differentiation are manufactured under GMP conditions at sites that use methods and controls that conform to current Good Manufacturing Practices (cGMP) for medical devices. These manufacturing sites are ISO 13485 and ISO 9001certified, and the rigorous practices we adhere to at these sites help ensure the consistency, reliability, and high quality of a wide variety of iPSC therapy workflow reagents.
To further help you maximize the potential of your research and streamline your transition to the clinic, we offer Gibco Cell Therapy Systems (CTS) equivalents for many of our research-use products. In addition to GMP manufacturing, Gibco CTS products undergo quality control testing and are accompanied by appropriate documentation so you can transition your cell therapy to the clinic with confidence.
*Adherence to supplier related responsibilities of USP<1043>
First off-the-shelf reprogramming system manufactured in accordance with GMP requirements. CTS CytoTune 2.1 kit offers high-efficiency Sendai delivery of reprogramming factors.
Click image to enlarge
Efficient reprogramming from adult human dermal fibroblasts, T cells, and CD34+ cells. These data demonstrate that the CytoTune-iPS 2.1 kit can be used to successfully reprogram human dermal fibroblasts (HDFa), T cells, and CD34+ cells.
Gibco CTS Essential 6 Medium is a xeno-free, feeder-free, cGMP-manufactured medium which supports the spontaneous or directed differentiation of human pluripotent stem cells (PSCs) and the reprogramming of somatic cells.
Based on the widely cited Gibco Essential 8 Medium, Gibco CTS Essential 8 Medium is the first globally available human- and animal originfree culture medium for human pluripotent stem cells (hPSCs) and is designed to meet international regulatory requirements for cell therapy.
Click image to enlarge
Using Applied Biosystems TaqMan hPSC Scorecard Panel analysis, Gibco CTS Essential 8 Medium and research-use-only Essential 8 Medium were shown to support comparable expression of PSC markers and lineage markers in undifferentiated PSCs and PSC-derived embryoid bodies.
CTS Vitronectin (VTN-N) Recombinant Human Protein is a defined matrix for feeder-free culture of iPSCs. Designed in the laboratory of James Thomson, this recombinant protein is intended for use with the CTS Essential 8 culture system.
CTS RevitaCell Supplement (100X) is an animal-origin-free, chemically defined supplement used with PSCs for post-thaw recovery or in combination with CTS Essential 8 Medium for single cell passaging. To minimize both the loss of cell viability and differentiation of PSCs, use the CTS PSC Cryopreservation Kit.
CTS Versene is a gentle non-enzymatic cell dissociation reagent for use in routine clump passaging of PSCs while maintaining viability over multiple passages.
For the cryopreservation and recovery of PSCs, the CTS PSC Cryopreservation Medium and CTS RevitaCell Supplement minimize the loss of cell viability and maximize post-thaw recovery when used in combination. Both reagents are included in the CTS PSC Cryopreservation Kit.
The CTS PSC Cryopreservation Medium is a xeno-free solution for the cryopreservation of pluripotent stem cells (PSCs). Both CTS PSC Cryopreservation Medium and CTS RevitaCell supplement are included in the CTS PSC Cryopreservation Kit that helps minimize loss of cell viability and maximize post-thaw recovery.
CTS KnockOut SR XenoFree Medium is a defined, xeno-free serum replacement based on the traditional Gibco KnockOut Serum Replacement, which has been cited in more than 2,000 publications and trusted for over 20 years.
Maintenance of pluripotency using CTS KNOCKOUT SR XenoFree Medium. Following 10 passages in either KSR (left lane) or KSR XenoFree CTS (right lane) on HFF attached with CELLstart substrate, BG01v gene expression was examined (top). Gene expression of embryoid bodies generated from the same P10 BG01v/HFF cultures (bottom).
Your choice of chemically defined human- and animal origin-free basal media for pluripotent stem cell culture. Based on traditional DMEM and DMEM/F12 formulations, these basal media are:
We offer full customization options to help meet your unique specifications for any project. Flexibility is yours in creating your own Gibco custom cell culture medium
Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.
View original post here:
Induced Pluripotent Stem Cell (iPSC) Media and Reagents ...
- Exclusive: Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer - Endpoints News - December 18th, 2024
- Sumitomo Chemical and Sumitomo Pharma to Establish Regenerative Medicine and Cell Therapy Joint Venture - - December 18th, 2024
- Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic - The Eastern Progress Online - December 18th, 2024
- BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT... - December 18th, 2024
- Induced Pluripotent Stem Cells: Problems and Advantages when Applying ... - December 9th, 2024
- How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando - geneonline - November 29th, 2024
- Toward Personalized Cell Therapies by Using Stem Cells 2013: BioMed Research International - Wiley Online Library - November 15th, 2024
- Cell therapy for heart disease and therapeutic cloning: will embryos re-enter the stem cell race? - Genethique - November 15th, 2024
- Cutting-edge stem cell therapy proves safe, but will it ever be ... - AAAS - November 6th, 2024
- Induced pluripotent stem cell - Wikipedia - October 21st, 2024
- What are iPS cells? | For the Public | CiRA | Center for iPS Cell ... - October 21st, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 13th, 2024
- iPSCs Manufacturing for Cell-Based Therapies: A Market Analysis of Cell Types, Therapeutic Applications, Ma... - WhaTech - August 4th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 14th, 2024
- Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple... - March 1st, 2023
- What is an Intrusion Prevention System? Definition ... - Fortinet - January 27th, 2023
- What is an IPS Monitor? Monitor Panel Types Explained ... - January 27th, 2023
- IPS panel - Wikipedia - January 27th, 2023
- Cell and gene therapy products: what is an ATMP? - The Niche - January 3rd, 2023
- Cell Therapy - an overview | ScienceDirect Topics - November 22nd, 2022
- Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - November 6th, 2022
- Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022 - November 6th, 2022
- Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update - November 6th, 2022
- NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting - November 6th, 2022
- Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core... - November 6th, 2022
- CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver... - November 6th, 2022
- Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference - November 6th, 2022
- Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection - November 6th, 2022
- PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors - November 6th, 2022
- ORYZON to Give Updates on Corporate Progress in November - November 6th, 2022
- Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022 - November 6th, 2022
- Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver... - November 6th, 2022
- First U.S. patient receives autologous stem cell therapy to treat dry ... - October 29th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - Yahoo Finance - October 13th, 2022
- iPS-Cell Based Cell Therapies for Genetic Skin Disease - October 5th, 2022
- Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com - October 5th, 2022
- MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress - Yahoo... - October 5th, 2022
- Stem Cells Market Size Expected to Reach USD 19.31 Billion by 2028: Increasing Number of Clinical Trials Across the Globe - Digital Journal - September 27th, 2022
- Implanting a Patient's Own Reprogrammed Stem Cells Shows Early Positive Results for Treating Dry AMD - Everyday Health - September 19th, 2022
- Current status of umbilical cord blood storage and provision to private biobanks by institutions handling childbirth in Japan - BMC Medical Ethics -... - September 19th, 2022
- Global Induced Pluripotent Stem Cells Market (2022 to 2027) - Growth, Trends, Covid-19 Impact and Forecasts - ResearchAndMarkets.com - Business Wire - September 11th, 2022
- Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials... - September 11th, 2022
- Improving the differentiation potential of pluripotent stem cells by optimizing culture conditions | Scientific Reports - Nature.com - August 26th, 2022
- New research digs into the genetic drivers of heart failure, with an eye to precision treatments - STAT - August 10th, 2022
- Creative Biolabs Leads the Forefront of iPSC Technology - Digital Journal - August 10th, 2022
- The zinc link: Unraveling the mechanism of methionine-mediated pluripotency regulation - EurekAlert - July 25th, 2022
- Live Cell Metabolic Analysis Paving the Way for Metabolic Research and Cell & Gene Therapy, Upcoming Webinar Hosted by Xtalks - Benzinga - July 16th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 8th, 2022
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - June 30th, 2022
- The benefits and risks of stem cell technology - PMC - June 30th, 2022
- The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies - Neurology Live - June 20th, 2022
- Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology... - June 11th, 2022
- Newsletter April 2022 - Progress in Cline's cell lab and in the stem cell therapy field - Marketscreener.com - April 29th, 2022
- Healios K K : Joint Research with the Division of Regenerative Medicine, the Institute of Medical Science for Developing a Mass Production Method of... - April 3rd, 2022
- A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy - March 22nd, 2022
- The Pipeline for of iPSC-Derived Cell Therapeutics in 2022 ... - March 22nd, 2022
- Cell Therapy Processing Market CAGR of 27.80% Share, Scope, Stake, Trends, Industry Size, Sales & Revenue, Growth, Opportunities and Demand with... - January 3rd, 2022
- Stem cell therapy for diabetes - PubMed Central (PMC) - November 22nd, 2021
- Stem cells: Therapy, controversy, and research - October 5th, 2021
- How much does stem cell therapy cost in 2021? - The Niche - October 5th, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 5th, 2021
- Exclusive Report on Stem Cell Therapy in Cancer Market | Analysis and Opportunity Assessment from 2021-2028 |Aelan Cell Technologies, Baylx, Benitec... - August 6th, 2021
- Asia-Pacific Cell Therapy Market 2021-2028 - Opportunities in the Approval of Kymriah and Yescarta - PRNewswire - August 6th, 2021
- Base Editing as Therapy for Common Inherited Lung and Liver Disease Shows Promise - Clinical OMICs News - July 22nd, 2021
- MoHAP, EHS reveal immunotherapy for cancer, viral infections at Arab Health 2021 - WAM EN - June 25th, 2021
- Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Nez as Chief... - June 8th, 2021
- Cryopreservation Media helps in Development of a Cell Therapy for Parkinson's Disease - Microbioz India - June 8th, 2021
- Accelerated Biosciences' Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and... - May 15th, 2021
- Factor Bioscience to Deliver Six Digital Presentations at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting - PRNewswire - May 15th, 2021
- St. Jude's $11.5B, six-year plan aims to improve global outcomes for children with cancer and catastrophic diseases - The Cancer Letter - May 15th, 2021
- Synthego Launches Eclipse Platform to Accelerate Research and Development of Next-generation Medicines - The Scientist - April 19th, 2021
- The Google Play video app will leave Roku, Vizio, LG and Samsung's TV platforms - Yahoo Canada Finance - April 19th, 2021
- New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News - March 8th, 2021
- Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymphoma - Targeted Oncology - March 8th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 14th, 2021
- A Potential Therapy for One of the Leading Causes of Heart Disease - PRNewswire - December 10th, 2020
- Evotec and Sartorius Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach - BioSpace - December 9th, 2020
- Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020 - November 28th, 2020
- Induced Pluripotent Stem Cell - an overview ... - November 28th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 28th, 2020